

Newport Beach and Birch Street

Clinical Research Treatment Trial Flowchart

AML NEWLY DIAGNOSED: NON-INTENSIVE

UCI 21-216

Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

FLT3 mutation

Mechanism: FLT3 inhibitor

PI: Jeyakumar

Coord: S. Osorio

Accrual: 2/5

CLL NEWLY DIAGNOSED: HIGH RISK

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs

Coord: K. McAbee

Accrual: 4/10

GASTRIC/GEJ: NEWLY DIAGNOSED METASTATIC

ECOG EA2183

(SOC + XRT)

PI: Hong
Coord: J. Koff
Accrual: 1/7

GASTRIC/GEJ: NEOADJUVANT

UCI 21-191

(SOC therapy with ctDNA testing)

PI: Dayyani
Coord: A. Luna
Pending activation

NON-TREATMENT/BASIC SCIENCE

UCI 18-136

PI: Parajuli
Coord: B. Sanchez
Accrual: 74/100

UCI 17-05 (BRCA1 -/+)

PI: Parajuli
Coord: B. Sanchez
Accrual: 48/75

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

ADJUVANT

ALLIANCE A011801 (HER2+)

Antibody drug conjugate + kinase inhibitor

PI: Parajuli
Coord: S.Ruiz
Accrual: 4/10

1L METASTATIC

2L METASTATIC

3L METASTATIC

ETCTN 10546 (TNBC)

Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)

PI: Parajuli; Coord: A. Chavez

Accrual: 1/5

UCI 19-145 (HR+/HER2-)

CDK 4/6 inhibitor + ER Regulator + Aromatase Inhibitor

PI: Mehta; Coord: S. Ruiz, P. Cabanting

Accrual: 18/20

UCI 22-139 (HR+/HER2-)

PI3K/mTOR inhibitor

PI: Parajuli; Coord: R. Kang

Accrual: 4/5

HCC: LOCOREGIONAL

UCI 19-49

Cabo + Ipi/Nivo + TACE

PI: Dayyani
Coord: Han Nguyen
Accrual: 19/35

HCC: 1-3L

UCI 22-106

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab

PI: Dayyani
Coord: H. Nguyen
Accrual: 8/10

PANCREATIC: BORDERLINE/LOCALLY ADVANCED

ETCTN 10366

M3814 (Peposertib) + radiation therapy

PI: Dayyani
Coord: S. Duong
Accrual: 6/8

MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
Coord: A. Reipolska
Accrual: 84/90

SARCOMA: RECURRENT

ETCTN 10556

Ipilimumab and Nivolumab +/- Cabozantinib

PI: Chow
Coord: B. Huynh
Accrual: 3/5

Neo-adjuvant or Adjuvant HNSCC

HN009

Cisplatin Q3 weeks vs Weekly
Locally Advanced HNSCC

Coord: A. Reipolska
Accrual: 1/5

KRAS**UCI 22-75**

KRAS targeted Vaccine

PI: Valerin
Coord: M. Duron
Accrual: 5/7

CLDN18.2**UCI 21-10**

Bispecific antibody (anti-CLDN18.2 + anti-4-1BB)

PI: Dayyani
Coord: K. Ghio
Accrual: 18/27